Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Cavalet Blanco (Porto Alegre, Brazil), L. Martins Becher (Porto Alegre, Brazil), L. Zani Da Silva (Porto Alegre, Brazil), C. Rocha Dullius (Porto Alegre, Brazil), F. Kahan (Porto Alegre, Brazil), S. Rocha Machado (Porto Alegre, Brazil), J. Miguel Chatkin (Porto Alegre, Brazil). Is omalizumab response influenced by passive smoking in severe asthma?. 1129

Member's Comments

No comment yet.

Related content which might interest you: The influence of smoking on the treatment response in patients with asthma Source: Annual Congress 2007 - PG15 - Difficult-to-treat asthma: dealing with smoker patients Year: 2007 The effect of passive smoking on severity of children asthma Source: Eur Respir J 2001; 18: Suppl. 33, 453s Year: 2001 Are severe asthmatics still smoking? Source: International Congress 2017 – Smoking and health hazards Year: 2017 Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Are a degree of asthma therapy related to asthma control impairment? Source: Eur Respir J 2003; 22: Suppl. 45, 370s Year: 2003 Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 The value of behavioral regulation in patients with bronchial asthma in case of smoking cessation Source: International Congress 2019 – From tobacco-related comorbidities to tobacco cessation Year: 2019 Passive smoking and the airways reaction to inhaled corticosteroid therapy in children with asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Does FENO predict FEV1 response to exposure cessation in occupational asthma? Source: Annual Congress 2012 - Occupational asthma Year: 2012 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Passive smoking, asthma and asthma severity in the EGEA study Source: Eur Respir J 2001; 18: Suppl. 33, 373s Year: 2001 Returning asthma symptoms correlate with free IgE upon omalizumab cessation Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Impact of prior smoking exposure and COPD comorbidity on treatment response to monoclonal antibodies in patients with severe asthma Source: ERJ Open Res, 7 (3) 00190-2021; 10.1183/23120541.00190-2021 Year: 2021 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 An increase in bronchial responsiveness is associated with continuing or restarting smoking Source: Annual Congress 2005 - Highlights of asthma epidemiology Year: 2005 What influences the response to training of inhalation technique in patients with asthma and COPD? Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018 Which are the factors and causes that lead to omalizumab withdrawal in severe asthma patients? Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 The airways response to inhaled corticosteroid therapy in children with asthma exposed to environmental tobacco smoke Source: Annual Congress 2013 –Passive smoking, children and students (young adults) Year: 2013 Greater risk of incident asthma cases in adults with allergic rhinitis: importance of cigarette smoking Source: Annual Congress 2006 - New investigational approaches to smoking and smoking cessation Year: 2006 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005